Article

Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance

Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA.
Journal of Virology (Impact Factor: 4.65). 03/2012; 86(11):6315-22. DOI: 10.1128/JVI.00050-12
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) infection significantly increases the prevalence of type 2 diabetes mellitus (T2DM). Insulin receptor substrate 1 (IRS-1) plays a key role in insulin signaling, thus enabling metabolic regulation in mammalian cells. We have previously shown that HCV infection modulates phosphorylation of Akt, a downstream target of IRS-1. In this study, we further examined the status of total IRS-1 and the downstream regulation of the Akt pathway in understanding mTOR/S6K1 signaling using HCV genotype 2a (clone JFH1)-infected hepatocytes. Inhibition of IRS-1 expression was observed in HCV-infected hepatocytes compared to that in a mock-infected control. The status of the tuberous sclerosis complex (TSC-1/TSC-2) was significantly decreased after HCV infection of human hepatocytes, showing a modulation of the downstream Akt pathway. Subsequent study indicated an increased level of Rheb and mTOR expression in HCV-infected hepatocytes. Interestingly, the phosphoS6K1 level was higher in HCV-infected hepatocytes, suggesting a novel mechanism for IRS-1 inhibition. Ectopic expression of TSC-1/TSC-2 significantly recovered the IRS-1 protein expression level in HCV-infected hepatocytes. Further analyses indicated that HCV core protein plays a significant role in modulating the mTOR/S6K1 signaling pathway. Proteasome inhibitor MG 132 recovered IRS-1 and TSC1/2 expression, suggesting that degradation occurred via the ubiquitin proteasome pathway. A functional consequence of IRS-1 inhibition was reflected in a decrease in GLUT4 protein expression and upregulation of the gluconeogenic enzyme PCK2 in HCV-infected hepatocytes. Together, these observations suggested that HCV infection activates the mTOR/S6K1 pathway in inhibiting IRS-1 function and perturbs glucose metabolism via downregulation of GLUT4 and upregulation of PCK2 for insulin resistance.

Download full-text

Full-text

Available from: Shubham Shrivastava, Jul 27, 2015
0 Followers
 · 
171 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The PI3K-AKT signaling pathway plays an important role in cell growth and metabolism. Here we report that HCV transiently activates the PI3K-AKT pathway. This activation was observed as early as 15 minutes post-infection, peaked by 30 minutes, and became undetectable at 24 hours post-infection. The activation of AKT could also be mediated by UV-inactivated HCV, HCV pseudoparticle (HCVpp) and the ectodomain of the HCV E2 envelope protein. Since antibodies directed against CD81 and claudin-1, but not antibodies directed against SR-BI or occludin, could also activate AKT, the interaction between HCV E2 and its two co-receptors CD81 and claudin-1 likely triggered the activation of AKT. This activation of AKT by HCV was important for HCV infectivity, as the silencing of AKT by siRNA or the treatment of cells with its inhibitors or with the inhibitor of its upstream regulator PI3K significantly inhibited HCV infection, whereas the expression of constitutively active AKT enhanced HCV infection. The PI3K-AKT pathway is likely involved in HCV entry, as the inhibition of this pathway could inhibit the entry of HCVpp but not the VSV pseudoparticle (VSVpp) into cells. Furthermore, the treatment of cells with the AKT inhibitor AKT-V prior to HCV infection inhibited HCV infection whereas the treatment after HCV infection had no obvious effect. Taken together, our studies indicated that HCV transiently activates the PI3K-AKT pathway to facilitate its entry. These results provide important information for understanding HCV replication and pathogenesis and raised the possibility of targeting this cellular pathway to treat HCV patients.
    Journal of Biological Chemistry 10/2012; 287(50). DOI:10.1074/jbc.M112.414789 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hantavirus pulmonary syndrome (HPS) is a severe respiratory disease characterized by pulmonary edema with a fatality of 35-45%. Disease occurs following infection by pathogenic New World hantaviruses, such as Andes virus (ANDV), which targets lung microvascular endothelial cells. During replication the virus scavenges 5' m(7)G-caps from cellular mRNA to ensure efficient translation of viral proteins by the host-cell cap-dependent translation machinery. In cells, mammalian target of rapamycin (mTOR) regulates the activity of host cap-dependent translation by integrating amino acid, energy, and oxygen availability signals. Since there is no approved pharmacological treatment for HPS, we investigated whether inhibitors of the mTOR pathway could reduce hantavirus infection. Here, we demonstrate that treatment with an FDA-approved rapamycin analogue (temsirolimus, CCI-779) blocks ANDV protein expression and virion release, but not entry into primary human microvascular endothelial cells. This effect was specific to viral proteins, as temsirolimus treatment did not block host protein synthesis. We confirmed that temsirolimus targeted host mTOR complex 1 (mTORC1) and not a viral protein as knockdown of mTORC1 and mTORC1 activators, but not mTOR complex 2 components reduced ANDV replication. Additionally, primary fibroblasts from a patient with tuberous sclerosis exhibited increased mTORC1 activity and increased ANDV protein expression, which was blocked following temsirolimus treatment. Finally, we show that ANDV glycoprotein Gn co-localizes with mTOR and lysosomes in infected cells. Together, these data demonstrate that mTORC1 signaling regulates ANDV replication and suggest that the hantavirus Gn protein may modulate mTOR and lysosomal signaling during infection, thus bypassing the cellular regulation of translation.
    Journal of Virology 11/2012; 87(2). DOI:10.1128/JVI.02415-12 · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin, insulin-like growth factor 1 (IGF-1), and IGF-2 are the most studied insulin-like peptides. These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as in the associated immune deregulations. A growing body of evidence suggests that insulin and IGF-1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus playing a pivotal role in cell fate determination. Despite of the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of insulin-like peptides as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening, and novel approaches to controlling tumor development.
    Endocrine Related Cancer 12/2012; 20(1). DOI:10.1530/ERC-12-0324 · 4.91 Impact Factor
Show more